We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Gilead Sciences Acquires EpiTherapeutics

News   May 07, 2015

 
Gilead Sciences Acquires EpiTherapeutics
 
 
Advertisement
 

RELATED ARTICLES

Your Cells Look Young for Their Age, Compared to a Chimp's

News

Part of the secret to human longevity, researchers say, may lie in chemical changes along the DNA within our cells that slowed the rate of human aging in the 7 to 8 million years since our ancestors went their separate ways from chimps.

READ MORE

Collaborations Aim to Meet Unmet Clinical Needs in Biomarker Discovery and Characterization

News

Thermo Fisher Scientific announced agreements with AstraZeneca and the University of Nebraska Medical Center that will showcase new workflows to improve the throughput, robustness and standardization of clinical biomarker analysis.

READ MORE

Epigenetic Therapy in Parents Protects Offspring From Ischemic Injury in Mouse Study

News

Ischemic retinopathies, including glaucoma and diabetic retinopathy, are major causes of visual morbidity and blindness. New research shows that an epigenetic therapy reduces retinal injury from acute ischemia, not only in the animals that receive the treatment, but also in their untreated first-generation offspring.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE